Journal of Clinical Oncology, Vol 17, Issue 4
(April), 1999: 1141
© 1999 American Society for Clinical Oncology
Clinical Features of Hypersensitivity Reactions to Carboplatin
Maurie Markman,
Alexander Kennedy,
Kenneth Webster,
Paul Elson,
Gertrude Peterson,
Barbara Kulp,
Jerome Belinson
From the Cleveland Clinic Cancer Center and Departments of Gynecology/Obstetrics and Hematology/Oncology, the Cleveland Clinic Foundation, Cleveland, OH.
Address reprint requests to Maurie Markman, MD, Department of Hematology/Medical Oncology, Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195; email markmam{at}cesmtp.ccf.org
PURPOSE: To characterize the clinical features of carboplatin-associated hypersensitivity reactions.
PATIENTS: Patients with gynecologic malignancies treated at the Cleveland Clinic Foundation from June 1995 through July 1998 who experienced a carboplatin-associated hypersensitivity reaction were the subjects of this evaluation.
RESULTS: Of the 205 patients treated with carboplatin during this time period, 24 (12%) developed a carboplatin hypersensitivity reaction. The median number of platinum (carboplatin plus cisplatin) courses for the first episode was eight (range, six to 21). Only three patients (13%) developed this toxicity during their initial chemotherapy regimen, with the remainder experiencing a reaction during their second (n = 15) or third (n = 6) carboplatin treatment program for recurrent disease. Thirteen patients (54%) developed at least moderately severe symptoms (diffuse erythroderma, tachycardia, chest tightness, wheezing, facial swelling, dyspnea, hypertension, or hypotension). In approximately one half of patients, the reaction developed after more than 50% of the carboplatin had been infused. Only one of three patients was successfully treated with the agent upon rechallenge.
CONCLUSION: Carboplatin hypersensitivity reactions develop in patients who have been extensively pretreated with the agent. The clinical features are highly variable, but they are sufficiently different from those noted after the administration of paclitaxel that it should not be difficult to distinguish between reactions to the two agents. As carboplatin is increasingly used as initial and second-line chemotherapy of ovarian cancer and other malignancies, it can be anticipated that hypersensitivity reactions to the drug will become a more common and difficult clinical management issue.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
C. H. Chung
Managing Premedications and the Risk for Reactions to Infusional Monoclonal Antibody Therapy
Oncologist,
June 1, 2008;
13(6):
725 - 732.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H.-J. Lenz
Management and Preparedness for Infusion and Hypersensitivity Reactions
Oncologist,
May 1, 2007;
12(5):
601 - 609.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. L de Lemos
Acute reactions to chemotherapy agents
Journal of Oncology Pharmacy Practice,
September 1, 2006;
12(3):
127 - 129.
[Abstract]
[PDF]
|
|
|
|
|
|
|
P. Viens, T. Petit, A. Yovine, P. Bougnoux, G. Deplanque, P.-H. Cottu, R. Delva, J.-P. Lotz, S. V. Belle, J.-M. Extra, et al.
A phase II study of a paclitaxel and oxaliplatin combination in platinum-sensitive recurrent advanced ovarian cancer patients
Ann. Onc.,
March 1, 2006;
17(3):
429 - 436.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. W. K. Siu, R. T. T. Chan, and G. K. H. Au
Hypersensitivity reactions to oxaliplatin: experience in a single institute
Ann. Onc.,
February 1, 2006;
17(2):
259 - 261.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. V. Ng
Hypersensitivity Reactions to Oxaliplatin in Two Asian Patients
Ann. Pharmacother.,
June 1, 2005;
39(6):
1114 - 1118.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. A. Cannistra
Cancer of the Ovary
N. Engl. J. Med.,
December 9, 2004;
351(24):
2519 - 2529.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. J. Herzog
Recurrent Ovarian Cancer: How Important Is It to Treat to Disease Progression?
Clin. Cancer Res.,
November 15, 2004;
10(22):
7439 - 7449.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Markman, J. Markman, K. Webster, K. Zanotti, B. Kulp, G. Peterson, and J. Belinson
Duration of Response to Second-Line, Platinum-Based Chemotherapy for Ovarian Cancer: Implications for Patient Management and Clinical Trial Design
J. Clin. Oncol.,
August 1, 2004;
22(15):
3120 - 3125.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Dimopoulou, E. Efstathiou, A. Samakovli, U. Dafni, L. A. Moulopoulos, C. Papadimitriou, P. Lyberopoulos, E. Kastritis, C. Roussos, and M. A. Dimopoulos
A prospective study on lung toxicity in patients treated with gemcitabine and carboplatin: clinical, radiological and functional assessment
Ann. Onc.,
August 1, 2004;
15(8):
1250 - 1255.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Markman, K. Zanotti, G. Peterson, B. Kulp, K. Webster, and J. Belinson
Expanded Experience With an Intradermal Skin Test to Predict for the Presence or Absence of Carboplatin Hypersensitivity
J. Clin. Oncol.,
December 15, 2003;
21(24):
4611 - 4614.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. J. Dunton
Management of Treatment-Related Toxicity in Advanced Ovarian Cancer
Oncologist,
October 1, 2002;
7(90005):
11 - 19.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. S. Dizon, M. L. Hensley, E. A. Poynor, P. Sabbatini, C. Aghajanian, A. Hummer, E. Venkatraman, and D. R. Spriggs
Retrospective Analysis of Carboplatin and Paclitaxel as Initial Second-Line Therapy for Recurrent Epithelial Ovarian Carcinoma: Application Toward a Dynamic Disease State Model of Ovarian Cancer
J. Clin. Oncol.,
March 1, 2002;
20(5):
1238 - 1247.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. M. Zanotti, L. A. Rybicki, A. W. Kennedy, J. L. Belinson, K. D. Webster, B. Kulp, G. Peterson, and M. Markman
Carboplatin Skin Testing: A Skin-Testing Protocol for Predicting Hypersensitivity to Carboplatin Chemotherapy
J. Clin. Oncol.,
June 15, 2001;
19(12):
3126 - 3129.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
